September 4, 2025 — Leads & Copy — PridCor Therapeutics LLC announced encouraging findings from a new preprint detailing a small, open-label Long COVID (LC) case series. The study, authored by William Pridgen, M.D., and David Putrino, Ph.D., found that a 15-day pulsed course of Paxlovid in addition to a 120-day regimen of valacyclovir and celecoxib (CAR) improved fatigue, dysautonomia, and brain fog in LC patients compared to those receiving the dual-drug regimen alone. Reported benefits were durable, with patients continuing to report improvements at approximately 305 and 731 days from treatment start.
The company reported that the CAR patients were reassessed at the 305-day and 731-day follow-up from their treatment start date and reported no measurable loss of efficacy demonstrating significant durability of treatment.
A formal double-blind, placebo-controlled, randomized clinical trial, the “SHIELD” study will be conducted at the Icahn School of Medicine at Mount Sinai beginning late 2025/early 2026.
The preprint is available on Research Square (DOI: 10.21203/rs.3.rs-7500476/v1) and has been submitted to a peer-reviewed journal for publication. The preprint can be viewed online at https://www.researchsquare.com/article/rs-7500476/v1
William Pridgen, M.D., is the principal investigator and CEO of PridCor Therapeutics. He can be contacted through pridgen@pridcor.com.
Source: PridCor Therapeutics LLC
